Genetic Immunity, InPlay: Company to Attend CLINAM European Conference for Clinical Nanomedicine

Genetic Immunity is pleased to announce that Julianna Lisziewicz,
Chief Executive Officer of the Company will be presenting at the
European Conference for Clinical Nanomedicine, to be held from April
26-29, 2009 at the Basel Convention Center in Basel, Switzerland.

"The participants of this conference are working on
nanotechnology-based drugs and biologics which have novel forms of
therapeutic functionality meant to improve their efficacy and limit
their negative side-effects. The interest in this clinical
nanomedicine conference suggests that European entrepreneurs can be
competitive globally and perhaps even spearhead the development of
Nanomedicines. With our lead Nanomedicine Vaccine, the DermaVir Patch
which is already in Phase II clinical trials, we are pioneering the
field of Nanovaccines. Nanovaccines are just emerging as potential
treatment and prevention solutions, and have recently gained
recognition in the treatment of HIV, cancer and hepatitis. I look
forward to exchange scientific and business information with other
participants at the conference," commented Julianna Lisziewicz, CEO
of the Company.

The European Conference for Clinical Nanomedicine is the annual
scientific conference uniting clinicians and nanoscientists who have
the common vision to apply nanoscience methods, tools and materials
to the benefit of patients. It is a conference with European emphasis
and international participation.

About Genetic Immunity

Genetic Immunity is a US/Hungarian development stage
biopharmaceutical company establishing leadership in Nanomedicines for
immune amplification. Nanomedicine, an offshoot of nanotechnology,
refers to highly specific medical intervention at the molecular scale
for treating disease or repairing damaged tissues. By leveraging its
proprietary immune amplification platform technology, the Company
aims to address new markets for infectious diseases, cancer and
allergies through the discovery, development and commercialization of
topically administered nanomedicines. These indications represent a
significant unmet medical need and the potential for alternative
treatment approaches. http://www.geneticimmunity.com

About Power of the Dream Ventures

Power of the Dream Ventures, Inc. is a leading technology holding
company. We identify and harness the unique technological prowess of
Hungary's high-tech industry, turning promising ideas and ready to
market products/technologies into global industry leaders. We focus on
developing, acquiring, licensing, or co-developing technologies that
originate exclusively in Hungary that are in prototype stage based on
existing patents; in prototype stage prior to patenting; existing
products that require expansion capital to commercialize; emerging
science and high-technology research projects that require help in
patenting, developing the product and marketing, University spin-off
technologies, and ideas from the very early stage that represent
"disruptive technologies." We primarily focus on providing enabling
solutions in the fields of environmental technologies, power
generation and storage, software products and services,
biotechnology, medical devices and what we call 'disruptive
technologies.' For more information please visit our website at
http://www.powerofthedream.com.

Contact:

At Genetic Immunity:

Dr. Zsolt Lisziewicz
Chief Operating Officer
Phone: +36-1-272-0364
Fax: +36-1-272-0364

At Power of the Dream Ventures:

Viktor Rozsnyay
President and CEO
Phone: +36-1-456-6061
Fax: +36-1-456-6062

SOURCE: Power of the Dream Ventures, Inc.

For full details on (PWRV) PWRV. (PWRV) has Short Term PowerRatings at TradingMarkets. Details on (PWRV) Short Term PowerRatings is available at This Link.